The phase III DESTINY-Breast02 (NCT03523585) trial enrolled unresectable/metastatic HER2-positive BC patients previously treated with trastuzumab emtansine and observed 10.5% (n = 42) cases of T-DXd-related ILD. The gene discussed is ERBB2; the disease is breast cancer.